Diagnostics and cancer therapies firm Avacta today appeared to taunt the recently much criticized Innova ( ODX share price surges as FDA urges Innova to stop COVID-19 test sales ) with news today that its lateral flow test had been given registration by the EU.
Innova has been a supplier of choice for the UK government for rapid lateral flow tests – having received contracts worth over £3bn for its tests that are made in China.
The registration for the AffixDX SARS-CoV-2 antigen lateral flow test means that it can now put the product in the market in 27 countries in the EU, albeit for professional use.
Seizing the opportunity to highlight the importance of its tests being British through-and-through, CEO Alastair Smith highlighted:
“This excellent performance and ease of nasal sampling, coupled with the fact that the AffiDX test is has been developed in the UK, is based on UK technology and is manufactured in the UK, are huge selling points for customers in Europe.”
The popular stock added that it currently has a number of commercial opportunities in the pipeline and that the registration was the last step required to full commercialisation of the test.
Shares in Avacta surged by over 12 percent following the news, while Omega Diagnostics also continued yesterday’s gain train with a 5% gain during the early afternoon.